Group items tagged

In recent years, somatic cells as therapeutic agents have provided new treatment approaches for a number of pathological conditions that were deemed untreatable, or difficult to treat. Several successful cell therapies using T cells have been demonstrated for cancer and autoimmune diseases, while stem cell therapies have given relief for heart disease and stroke. Hundreds of clinical trials are ongoing to examine efficacy of cell therapies for a variety of other diseases including diabetes, Alzheimer's, Parkinson's, and Crohn's disease. Production of therapeutic cells is currently expensive and, therefore, cost prohibitive for the large number of people who might benefit from these treatments. The overarching goal of this Advanced Biomanufacturing of Therapeutic Cells (ABTC) solicitation is to catalyze well-integrated interdisciplinary research to understand, design, and control cell manufacturing systems and processes that will enable reproducible, cost-effective, and high-quality production of cells with predictable performance for the identified therapeutic function.

In recent years, somatic cells as therapeutic agents have provided new treatment approaches for a number of pathological conditions that were deemed untreatable, or difficult to treat. Several successful cell therapies using T cells have been demonstrated for cancer and autoimmune diseases, while stem cell therapies have given relief for heart disease and stroke. Hundreds of clinical trials are ongoing to examine efficacy of cell therapies for a variety of other diseases including diabetes, Alzheimer's, Parkinson's, and Crohn's disease. Production of therapeutic cells is currently expensive and, therefore, cost prohibitive for the large number of people who might benefit from these treatments. The overarching goal of this Advanced Biomanufacturing of Therapeutic Cells (ABTC) solicitation is to catalyze well-integrated interdisciplinary research to understand, design, and control cell manufacturing systems and processes that will enable reproducible, cost-effective, and high-quality production of cells with predictable performance for the identified therapeutic function.

Scientists and patient advocacy groups often use a series of photos, commissioned by NEI some thirty years ago, when they wish to depict the visual experience of patients suffering from blinding diseases. At the time they were created, these images reflected the field's understanding of visual perception for such patients. But the field has advanced considerably since then, and these static images are considered overly simplistic, inaccurate, and generally unsatisfactory. At the same time, technology has evolved to where it is possible to use video and virtual reality to more authentically demonstrate (or even simulate) the experience of have a blinding disease. As part of the efforts of the NEI 50th Anniversary Planning Committee, the institute seeks the support of experts in blinding diseases, visual psychophysics, and video/virtual reality production to create a scientifically accurate and clinically authentic blindness simulation "experience" that can be used for education, public advocacy, and research purposes and a series of short videos that can be posted online for education and public outreach.

This FOA invites applications for the Microphysiological Systems (MPS) for Disease Modeling and Efficacy Testing Program to develop highly reproducible and translatable in vitro models for preclinical efficacy studies through discovery and validation of translatable biomarkers, development of standardized methods for preclinical efficacy testing and definitive efficacy testing of candidate therapeutics using best practices and rigorous study design. An essential feature will be a multidisciplinary approach that brings together experts in bioengineering, microfluidics, material science, "omic" sciences, computational biology, disease biology, pathology, electrophysiology, pharmacology, biostatistics and clinical science.

This FOA invites applications for the Microphysiological Systems (MPS) for Disease Modeling and Efficacy Testing Program to develop highly reproducible and translatable in vitro models for preclinical efficacy studies through discovery and validation of translatable biomarkers, development of standardized methods for preclinical efficacy testing and definitive efficacy testing of candidate therapeutics using best practices and rigorous study design. An essential feature will be a multidisciplinary approach that brings together experts in bioengineering, microfluidics, material science, "omic" sciences, computational biology, disease biology, pathology, electrophysiology, pharmacology, biostatistics and clinical science.

The PRP Impact Award mechanism is being offered for the first time in FY16.The Impact Award encourages applications that support the full spectrum of research projects or ideas that specifically focus on scientific and clinical Parkinson's disease issues, which, if successfully addressed, have the potential to make a major impact in preventing or halting the progression of Parkinson's disease or enhancing the well-being of individuals experiencing the impact of the disease

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) requests applications for the NIAMS Core Centers for Clinical Research (CCCR) (P30) within its mission. The CCCRs will provide avenues to advance the methodological sciences that support clinical research within and across the NIAMS' portfolio of diseases. The overall goals of the CCCR are to advance prevention, diagnosis and treatment of musculoskeletal, rheumatologic, and skin diseases by developing and fostering the implementation of novel methods, metrics, and outcome measures that address critical existing and emerging clinical research needs. 

The purpose of this Funding Opportunity Announcement (FOA) is to encourage small businesses to address the technological needs of the Kidney Precision Medicine Project (KPMP). The KPMP will obtain and evaluate kidney biopsies from participants with acute kidney injury (AKI) and chronic kidney disease (CKD), create a kidney tissue atlas, define disease subgroups, and identify critical cells, pathways and targets for novel therapies. Proposed technologies are expected to improve the safety of the human kidney biopsy or enhance interrogation of human kidney tissue, thus ensuring that the kidney biopsy yields useful research or clinical information.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage small businesses to address the technological needs of the Kidney Precision Medicine Project (KPMP). The KPMP will obtain and evaluate kidney biopsies from participants with acute kidney injury (AKI) and chronic kidney disease (CKD), create a kidney tissue atlas, define disease subgroups, and identify critical cells, pathways and targets for novel therapies. Proposed technologies are expected to improve the safety of the human kidney biopsy or enhance interrogation of human kidney tissue, thus ensuring that the kidney biopsy yields useful research or clinical information.

The purpose of this FOA is to invite applications that will seek to prospectively define and/or validate pulmonary or immune system attributes associated with pre-symptomatic disease states or resilience, with the goal of informing the development of primary prevention strategies for chronic lung diseases.

The NIH Blueprint for Neuroscience Research is a collaborative framework through which 14 NIH Institutes, Centers and Offices jointly support neuroscience-related research, with the aim of accelerating discoveries and reducing the burden of nervous system disorders. This Funding Opportunity Announcement (FOA) will solicit research projects to facilitate the development and translation of tools and technology for non-invasive imaging and profiling of human central nervous system (CNS, including retina) small blood and lymphatic vessels; to investigate their role in CNS physiology, disease, repair processes, and responses to therapy using novel approaches. Applications can be focused on the development of new technology and tools, novel target or biomarker identification and validation studies, or a combination of mechanistic and technology development studies specific to human CNS small blood and lymphatic vessels in health and disease, across the life span.

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes.

This Funding Opportunity Announcement (FOA) requests applications to explore human pancreatic tissues for the discovery of early biomarkers of T1D pathogenesis, the description of specific signaling or processing pathways that may contribute to the asymptomatic phase of T1D, the development of clinical diagnostic tools for the detection and staging of early T1D in at-risk or recently-diagnosed individuals, and/or the identification of therapeutic targets for the development of preventative or early treatment strategies. Successful applicants will join the Consortium on Beta Cell Death and Survival (CBDS), whose mission is to better define and detect the mechanisms of beta cell stress and destruction central to the development of T1D in humans, with the long-term goal of detecting beta cell destruction and protecting the residual beta cell mass in T1D patients as early as possible in the disease process, and of preventing the progression to autoimmunity. The CBDS is part of a collaborative research framework, the Human Islet Research Network (HIRN, https://hirnetwork.org), whose overall mission is to support innovative and collaborative translational research to understand how human beta cells are lost in T1D, and to find innovative strategies to protect and replace functional beta cell mass in humans. This FOA will only support studies with a primary focus on increasing our understanding of human disease biology (as opposed to rodent or other animal models).

This single-source funding opportunity announcement (FOA) Enhancing Public Health Emergency Preparedness and Response Capacities in the Americas in Collaboration with the National Center for Prevention Programs and Disease Control (CENAPRECE) in Mexico invites an application for a five-year cooperative agreement between the Department of Health and Human Services(HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) and the U.S.-Mexico Foundation for Science (FUMEC) to support CENAPRECE (an agency within Mexico Secretariat of Health [SALUD]). The envisioned ASPR-FUMEC-CENAPRECE collaboration sustains and advances the long-standing relationship between the United States and Mexico aimed at safeguarding each country from public health threats and fulfilling the goals of multiple international frameworks and agreements, including the International Health Regulations (2005) (IHR) (http://www.who.int/ihr/publications/9789241580496/en/). Projects and activities proposed by CENAPRECE for this agreement will combine strategic coordination of public health preparedness and emergency response programs as well as technical collaborations to strengthen the capacities of both countries and the region to prevent, detect, report, and respond to public health emergencies of all types, focusing on pandemic influenza, other emerging infectious diseases, and chemical, biological, and radiological (terrorism) hazards.

The purpose of this FOA is to invite applications that investigate aspects of lymphatic vessel physiology, development and pathophysiology related to health and diseases of the digestive system. Studies to understand the factors that control local lymphatic vessel functional anatomy and physiology and development during health or disease in this system and its organs, and the mechanisms by which alterations of lymphatic vessel function affect organ function, are of interest. However, studies with the major focus on immune mechanisms, role of lymphatics in cancer metastasis and study of lymphatic vessels in organs other than those from the digestive system will not be considered responsive.

The Paralyzed Veterans of America Education Foundation, a grantmaking organization of Paralyzed Veterans of America, seeks to fund innovative educational projects that enhance the quality of life of individuals with spinal cord injury or disease (SCI/D) and/or that increase the knowledge and effectiveness of health professionals in the SCI/D community. The foundation generally supports five types of projects: 1) Consumer, caregiver, and community education demonstration projects that seek to improve the health, independence, and quality of life of individuals with spinal cord injury or disease; 2) Professional development and education programs that improve the knowledge and competencies of professionals providing health care and related services to the SCI/D community, or fellowship/traineeship programs for professionals providing health care and related services to the SCI/D community; 3) Research utilization and dissemination projects that translate research findings into practice; 4) Assistive technology demonstration projects that improve the identification, selection, and use of assistive devices by people with SCI/D; and 5) Conferences and symposia designed to provide education and opportunities for collaboration among members of the SCI/D community.

The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research focused on biobehavioral or technological interventions to attenuate cognitive decline in individuals with dementia (such as Alzheimers disease, Lewy body dementia, vascular dementia), mild cognitive impairment (MCI), or disease- or age-related cognitive decline. There is particular interest in interventions that can be implemented in community settings by the affected individual, informal caregivers, or others in the community. Research to inform the development of such interventions is also of interest, as well as research examining underlying mechanisms and biomarkers associated with response to interventions. It is anticipated that the results of this research will help affected individuals maintain independence and quality of life, improve their ability to perform activities of daily living (ADLs) and instrumental activities of daily living (IADLs), and additionally help to reduce stress, burden, and other poor outcomes in their caregivers.

The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research focused on biobehavioral or technological interventions to attenuate cognitive decline in individuals with dementia (such as Alzheimer's disease, Lewy body dementia, vascular dementia), mild cognitive impairment (MCI), or disease- or age-related cognitive decline. There is particular interest in interventions that can be implemented in community settings by the affected individual, informal caregivers, or others in the community. Research to inform the development of such interventions is also of interest, as well as research examining underlying mechanisms and biomarkers associated with response to interventions. It is anticipated that the results of this research will help affected individuals maintain independence and quality of life, improve their ability to perform activities of daily living (ADLs) and instrumental activities of daily living (IADLs), and additionally help to reduce stress, burden, and other poor outcomes in their caregivers.   

The NIH Blueprint for Neuroscience Research is a collaborative framework through which 14 NIH Institutes, Centers and Offices jointly support neuroscience-related research, with the aim of accelerating discoveries and reducing the burden of nervous system disorders. This Funding Opportunity Announcement (FOA) will solicit research projects focused on the development of new technology and tools, or novel mechanistic studies, or a combination of mechanistic and technology development studies specific to central nervous system (CNS, which includes retina) small blood and lymphatic vessels in health and disease, across the life span. The program aims at facilitating the development of tools and technology to image, profile and map CNS small blood and lymphatic vessels. Additional goals are to elucidate the mechanisms underlying CNS small blood and lymphatic vessels structural and functional heterogeneity, differential susceptibility to injury, role in disease and repair processes, and their responses to therapies. Preclinical studies using in vitro and/or animal models specific to CNS small blood and lymphatic vessels alone or in combination with pilot human studies are appropriate for this FOA.

The American Gastroenterological Association is accepting applications for its AGA-Elsevier Gut Microbiome Pilot Research Award. The objectives of the program are to help early-career investigators establish their research careers and support research projects that represent new directions for established investigators. Projects must focus on the relationship of gut microbiota to digestive health and disease. To that end, a single one-year grant of $25,000 will be awarded to a recipient at any career stage for research on the relationship of gut microbiota to digestive health and disease. To be eligible, applicants must hold an MD, PhD, or equivalent degree (e.g., MBChB, MBBS, DO) and have a full-time faculty position at an accredited institution in North America. AGA membership is required at the time of application. Women and minorities are strongly encouraged to apply.

The purpose of this FOA is the rapid and efficient translation of innovative laboratory research findings into therapies, devices or other resources for use by clinicians to treat visual system diseases or disorders. Multidisciplinary teams of scientists and clinicians must focus on generating preclinical data that will lead to the development of biological interventions, such as gene therapy, cell-based therapy, pharmacological approaches, and/or medical devices. The ultimate goal of this program is to make technological, biological and pharmacological resources available to clinicians and their patients. Each project should have a well-defined end-point, achievable within a five-year time frame, of developing a device or treatment for a specific ocular disease.

The U.S. Department of Energy's Office of Science, Biological and Environmental Research (BER) hereby announces interest in receiving applications for genomics-based research that will lead to the improved use of plant biomass and feedstocks for the production of biofuels and renewable chemical feedstocks. Applications are sought for research on candidate herbaceous and woody plants with improved resistance/tolerance to disease and disease complexes, and non-food oil seed crops for improved winter cold tolerance/survivability and agronomic traits. Research to overcome these biological barriers to the low-cost, high-quality, scalable and sustainable production of dedicated bioenergy biomass feedstocks using the tools of genetics and genomics are encouraged.

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate translation of scientific discoveries and engineering developments in imaging, data science and/or spectroscopic technologies into methods or tools that address contemporary problems in understanding the fundamental biology, potential risk of development, diagnosis, treatment, and/or disease status for cancer or other disease.